Ozempic patient blinded by NAION sues Novo Nordisk
11 Articles
11 Articles
Court Ruling Limits Ozempic Copies in Favor of FDA, Novo Nordisk
A federal court in Texas has ruled against a trade group representing compounding pharmacies, siding with the Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk in a dispute over copies of the popular weight-loss and diabetes drugs Ozempic and Wegovy. The ruling, issued April 24 in the U.S. District Court for the Northern District of Texas, denied a request from the Outsourcing Facilities Association (OFA) to block the FD…
Court Ruling Limits Ozempic Copies in Favor of FDA, Novo Nordisk - The Thinking Conservative
Federal court ruled against trade group representing compounding pharmacies, siding with FDA and Novo Nordisk in dispute over copies of Ozempic and Wegovy. The post Court Ruling Limits Ozempic Copies in Favor of FDA, Novo Nordisk appeared first on The Thinking Conservative.
Ozempic Lawsuit: Diabetes Patient Claims Blindness – Archyde
Archyde “`html Ozempic Lawsuit: Blindness Claims Raise Concerns Maryland Man Sues ozempic Manufacturer, Alleging Drug-Induced Blindness A lawsuit filed in New Jersey claims Novo nordisk failed to warn patients about the risk of vision loss linked to its popular diabetes and weight-loss drug. May 1, 2025 A Maryland man who took Ozempic to manage his Type […] You can read the full story here: Ozempic Lawsuit: Diabetes Patient Claims Blindness.
Lawsuit alleges Maryland man with diabetes became blind after taking Ozempic – Mnnofa
A Maryland man who took Ozempic and then became legally blind is suing the drug’s manufacturer, arguing it had an obligation to warn patients that loss of sight could be a possible side effect. Todd Engel, 62, was prescribed Ozempic in 2023 to manage his Type 2 diabetes. The lawsuit said about four months later, Engel was diagnosed with nonarteritic anterior ischemic optic neuropathy, or NAION, a condition in which a loss of blood flow to the op…
Coverage Details
Bias Distribution
- 67% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage